Daily Chart

Pfizer Inc (PFE) Financial News - Merck Options Are Most Bearish Since 2006 Before Earnings

Pfizer Inc (PFE)

Merck Options Are Most Bearish Since 2006 Before Earnings

Quote: Pfizer Inc. (PFE) CEO who began his job a month before Frazier, has his New York-based company pursuing the sale or spinoff of at least two businesses as it faces patent losses on the cholesterol treatment Lipitor, the world’s best-selling drug, in November. No such plan has come from Frazier, who has only said he won’t rule out unit sales as he faces lost revenue next year from Singulair, with $5 billion in 2010 sales. Whitehouse StationNew Jersey, reports earnings tomorrow. Its puts cost 42 percent more than calls, near the 49 percent level reached July 25. That figure was the most since October 2006, Bloomberg data show. New York, said in a telephone interview. “People are waiting to see what Ken Frazier views the future of Merck as.” Merck shares have declined 3.1 percent this year while Pfizer’s shares jumped 11 percent. The Standard & Poor’s 500 Index advanced 3.4 percent while health-care stocks in the benchmark measure of U.S. shares climbed 8.7 percent. Three Options Merck has three opportunities to improve performance, Polischuk said. It could sell some divisions or older products as Pfizer is doing, it could acquire more companies, or it could focus on research over the long term and hope that its pipeline comes through despite recent stumbles, Polischuk said. Frazier “just hasn’t tipped his hand yet on which it is going to be,” he said. Steven Campanini, a spokesman for Merck, declined to comment. Seamus Fernandez, an analyst at Leerink Swann & Co. Pfizer’s animal health unit had sales last year of $3.48 billion. Singulair next year will follow Merck’s Cozaar and Hyzaar blood pressure medicines, which went off-patent in 2010, resulting in a 57 percent sales drop in the fourth quarter. Drug Pipeline This year, Merck has reported setbacks in its experimental drug pipeline. In January, it halted a trial of the bloodthinner vorapa...
Open whole article (external link)

Other Financial and Stock Market News concerning Pfizer Inc

Pfizer Inc Stock Summary

Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2015.